Probatebeta
Target

SSTR5

Somatostatin receptor type 5

As of the edition of 20 October 2026, SSTR5 (somatostatin receptor type 5, UniProt P35346) has 11 drugs tested at it and 18 companies on the list, 2 on route A and 7 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P35346
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
7
Disease areas
Cancer; Hormones; Digestive system; Nervous system; Bones, joints and muscles; Nutrition and metabolism; Urinary and reproductive; Inherited and neonatal
Registered trials of its drugs
400

Drugs at this target

StatusCount
Marketed6
Went quiet2
Stopped1
Withdrawn from market1
Status not established1
Total11
DrugStatusFurthest phaseUS protection
OctreotideMarketedPhase 4none listed
LanreotideMarketedPhase 4none listed
PasireotideMarketedPhase 4Ends 2026
Lutetium oxodotreotideMarketedPhase 4Ends 2031
SomatostatinMarketedPhase 4none listed
VeldoreotideWent quietPhase 2none listed
Indium pentetreotideMarketedPhase 4none listed
OnzigolideStoppedPhase 2none listed
DOTA-NOCWent quietPhase 3none listed
Lutetium-177Status not establishedNo phase statednone listed
Lutetium chlorideWithdrawn from marketNo phase statednone listed

11 of 11 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A2
Route B7
Engaged4
Undetermined5
Total on the list18
Three companies on route A or B, with the route only
CompanyRoute
IpsenRoute B
CuriumRoute B
Teijin PharmaRoute B

The other 15 companies at SSTR5

In the product

18 companies in all; 15 are not named here, and no score is.

See the 18 companies at SSTR5, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

Other targets in cancer

Companies holding approvals at SSTR5